MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
stock options
$1,517K
Net cash provided by
financing activities
$160K
Canceled cashflow
$1,357K
Net increase in
cash, cash...
-$216,925K
Canceled cashflow
$160K
Accounts payable and
accrued liabilities
$63,564K
Stock-based compensation
expense
$3,171K
Accrued compensation
and benefits
$879K
Non-cash operating lease
expense
$326K
Accrued indirect tax
liabilities
$138K
Depreciation and
amortization
$28K
Proceeds from
underwritten public...
-$1,215K
something is missing
-$137K
Proceeds from
at-the-market offering of...
-$5K
Net cash used in
investing activities
-$176,470K
Net cash used in
operating activities
-$40,615K
Canceled cashflow
$68,106K
Purchases of
available-for-sale investments
$176,470K
Net loss
-$83,233K
Prepaid expenses, other
current assets, and...
$24,971K
Operating lease
liabilities
-$349K
Accretion of discounts,
net of amortization...
$166K
Accounts receivable
$2K
Back
Back
Cash Flow
source: myfinsight.com
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)